
  
    
      
        Background_NNP
        Sulfasalazine_NNP (_( SSZ_NNP )_) is_VBZ a_DT widely_RB used_VBN and_CC highly_RB
        effective_JJ anti-inflammatory_JJ agent_NN in_IN the_DT treatment_NN of_IN
        Crohn_NNP 's_POS disease_NN and_CC ulcerative_JJ colitis_NNS [_NN 1_CD 2_CD 3_CD ]_NN ._. SSZ_NNP is_VBZ
        also_RB being_VBG used_VBN with_IN increasing_VBG frequency_NN in_IN the_DT treatment_NN
        of_IN various_JJ rheumatolgical_JJ disorders_NNS [_NN 4_CD 5_CD 6_CD 7_CD ]_NN ._. SSZ_NNP is_VBZ
        preferred_VBN over_IN other_JJ agents_NNS such_JJ as_IN gold_NN and_CC penicillamine_NN
        in_IN rheumatology_NN patients_NNS due_JJ to_TO its_PRP$ more_RBR favorable_JJ side_NN
        effect_NN profile_NN [_NN 8_CD 9_CD 10_CD ]_NN ._. Nonetheless_RB ,_, rash_NN ,_, fever_NN ,_, and_CC
        dyspepsia_NN occur_VB in_IN 3_CD %_NN to_TO 20_CD %_NN of_IN treated_VBN patients_NNS [_NN 7_CD 11_CD 12_CD
        ]_NN ._. These_DT reactions_NNS are_VBP usually_RB dose_NN dependent_JJ and_CC improve_VB
        with_IN dose_NN reduction_NN or_CC discontinuation_NN [_NN 7_CD 12_CD ]_NN ._. However_RB ,_,
        more_RBR serious_JJ but_CC less_RBR common_JJ side_NN effects_NNS have_VBP also_RB been_VBN
        reported_VBN [_NN 13_CD 14_CD 15_CD 16_CD 17_CD 18_CD 19_CD ]_NN ._. We_PRP now_RB report_VBP a_DT severe_JJ
        systemic_JJ reaction_NN to_TO SSZ_NNP in_IN a_DT 21_CD -_: year-old_JJ female_NN with_IN
        rheumatoid_NN arthritis_NN characterized_VBN by_IN granulomatous_JJ
        infiltration_NN of_IN the_DT bone_NN marrow_NN ,_, colon_NN and_CC small_JJ bowel_NN as_RB
        well_RB as_IN cholestatic_JJ hepatitis_NN and_CC seizures_NNS ._.
      
      
        Case_NNP Report_NNP
        A_DT 21_CD -_: year_NN old_JJ female_NN was_VBD diagnosed_VBN with_IN polyarticular_NN
        rheumatoid_NN arthritis_NN in_IN 1997_CD and_CC was_VBD managed_VBN with_IN naprosyn_NN
        (_( Naproxen_NNP ,_, Roche_NNP Laboratories_NNPS ,_, Nutley_NNP ,_, NJ_NNP )_) for_IN 4_CD years_NNS ._.
        Joint_NNP inflammation_NN was_VBD well_RB controlled_VBN with_IN
        hydroxychlorquine_NN (_( Plaquenil_NNP ,_, Sanofi_NNP Pharmaceuticals_NNP ,_, New_NNP
        York_NNP ,_, NY_NNP )_) from_IN October_NNP 1999_CD thru_NN June_NNP 2000_CD when_WRB
        hydroxychlorquine_NN was_VBD discontinued_VBN due_JJ to_TO persistent_JJ anemia_NN
        and_CC a_DT flare_VBP in_IN her_PRP$ arthritis_NN despite_IN adequate_JJ therapy_NN ._. The_DT
        patient_NN was_VBD started_VBN on_IN iron_NN supplementation_NN and_CC a_DT 4_CD -_: week_NN
        course_NN of_IN low_JJ dose_NN prednisone_NN in_IN June_NNP /_NN July_NNP 2000_CD ._. Due_JJ to_TO
        persistent_JJ arthritis_NN ,_, sulfasalazine_NN was_VBD initiated_VBN on_IN July_NNP
        28_CD ,_, 2000_CD at_IN a_DT dose_NN of_IN 500_CD mg_NN twice_RB daily_JJ ,_, increasing_VBG to_TO
        1000_CD mg_NN twice_RB daily_RB ._. Liver_NNP biochemistries_NNS were_VBD normal_JJ
        immediately_RB before_IN and_CC two_CD weeks_NNS after_IN initiating_VBG SSZ_NNP ._.
        Three_CD weeks_NNS after_IN starting_VBG SSZ_NNP ,_, the_DT patient_NN developed_VBD an_DT
        erythematous_JJ rash_NN over_IN the_DT upper_JJ extremities_NNS and_CC trunk_NN that_WDT
        improved_VBD with_IN cetirizine_NN (_( Zyrtec_NNP ,_, Pfizer_NNP Inc_NNP ,_, New_NNP York_NNP ,_,
        NY_NNP )_) ._. She_PRP then_RB developed_VBD fatigue_NN ,_, abdominal_NN pain_NN ,_, diarrhea_NN ,_,
        and_CC night_NN sweats_NNS which_WDT lead_VBP to_TO hospitalization_NN on_IN 8_CD /_NN 29_CD /_NN 00_CD
        and_CC SSZ_NNP was_VBD discontinued_VBN ._. At_IN presentation_NN ,_, serum_NN alkaline_NN
        phosphatase_NN was_VBD 923_CD IU_NNP /_NN L_NNP ,_, AST_NNP 105_CD IU_NNP /_NN L_NNP ,_, ALT_NNP 143_CD IU_NNP /_NN L_NNP ,_,
        bilirubin_NN 4_CD ._. 3_CD mg_NN /_NN dl_NN ,_, and_CC WBC_NNP was_VBD 9_CD ._. 6_CD k_NN /_NN l_NN with_IN 12_CD %_NN
        eosinophils_NNS ._. Over_IN the_DT next_JJ six_CD days_NNS ,_, she_PRP gained_VBD 20_CD pounds_NNS
        in_IN fluid_JJ weight_NN and_CC had_VBD fevers_NNS of_IN 103_CD °_NN F_NN despite_IN broad_JJ
        spectrum_NN antibiotics_NNS ._. She_PRP was_VBD transferred_VBN on_IN hospital_NN day_NN #_#
        6_CD to_TO the_DT University_NNP of_IN Michigan_NNP Medical_NNP Center_NNP for_IN further_JJ
        evaluation_NN and_CC management_NN ._.
        The_DT patient_NN reported_VBD a_DT prior_JJ history_NN of_IN infectious_JJ
        mononucleosis_NNS at_IN age_NN 18_CD and_CC was_VBD a_DT non-smoker_JJ and_CC consumed_VBN
        alcohol_NN infrequently_RB ._. She_PRP denied_VBD any_DT known_VBN drug_NN allergies_NNS
        or_CC prior_RB exposure_NN to_TO sulfa_NN containing_VBG medications_NNS or_CC
        antibiotics_NNS ._. There_EX was_VBD no_DT family_NN history_NN of_IN allergy_NN to_TO
        sulfa_NN products_NNS ._.
        On_IN hospital_NN day_NN #_# 6_CD ,_, the_DT patient_NN appeared_VBD toxic_JJ with_IN a_DT
        temperature_NN of_IN 102_CD °_NN F_NN ,_, pulse_NN 154_CD /_NN min_NN ,_, and_CC blood_NN pressure_NN of_IN
        100_CD /_NN 58_CD ._. Scleral_NNP icterus_JJ was_VBD present_JJ as_IN well_RB as_RB deeply_RB
        jaundiced_JJ ,_, edematous_JJ skin_NN with_IN a_DT macular_NN ,_, erythematous_JJ
        rash_NN ._. Non-tender_NNP ,_, 1_CD -_: 2_CD cm_NN lymph_NN nodes_NNS were_VBD palpated_JJ in_IN the_DT
        neck_NN ,_, axilla_NN ,_, and_CC groin_NN ._. There_EX were_VBD decreased_VBN breath_NN sounds_VBZ
        with_IN mild_JJ bibasilar_NN rales_NNS and_CC a_DT hyperdynamic_JJ precordium_NN ._.
        The_DT abdomen_NN was_VBD diffusely_RB tender_NN and_CC distended_JJ ._. Rectal_NNP
        examination_NN revealed_VBD brown_JJ hemoccult_NN +_NN stool_NN ._. Neurologic_NNP
        examination_NN was_VBD unremarkable_JJ ._.
        Laboratory_NN studies_NNS revealed_VBD a_DT WBC_NNP count_NN of_IN 44_CD ._. 2_LS ×_NN 10_CD 6_CD /_NN L_NNP
        with_IN 11_CD %_NN bands_NNS ,_, 24_CD %_NN neutrophils_NNS ,_, 30_CD %_NN lymphocytes_NNS ,_, 12_CD %_NN
        monocytes_NNS ,_, and_CC 22_CD %_NN eosinophils_NNS ._. The_DT WBC_NNP and_CC absolute_JJ
        neutrophil_NN count_NN nadired_JJ on_IN hospital_NN day_NN #_# 19_CD (_( Table_NNP 1_LS )_) ._.
        Hemoglobin_NNP was_VBD 9_CD ._. 3_CD g_SYM /_NN dl_NN ,_, platelets_NNS 336_CD ,_, 000_CD ,_, reticulocyte_NN
        count_NN 3_CD ._. 1_CD %_NN and_CC serum_NN ferritin_NN 17_CD ng_NN /_NN ml_NN ._. The_DT serum_NN alkaline_NN
        phosphatase_NN was_VBD 1002_CD IU_NNP /_NN L_NNP ,_, AST_NNP 57_CD IU_NNP /_NN L_NNP ,_, ALT_NNP 76_CD IU_NNP /_NN L_NNP ,_, total_JJ
        bilirubin_NN 6_CD ._. 6_CD mg_NN /_NN dl_NN ,_, albumin_NN 1_CD ._. 6_CD ,_, total_JJ protein_NN 3_CD ._. 6_CD g_SYM /_NN dl_NN
        and_CC INR_NNP 1_CD ._. 5_CD ._. Serum_NNP fibrinogen_NN was_VBD 126_CD mg_NN /_NN dl_NN and_CC d-dimer_JJ
        levels_NNS were_VBD elevated_VBD at_IN 0_CD ._. 2_CD -_: 0_CD ._. 40_CD mcg_NN /_NN ml_NN ._. Hepatitis_NNP A_DT ,_, B_NNP ,_,
        and_CC C_NNP serologies_NNS and_CC ANA_NNP and_CC ANCA_NNP were_VBD negative_JJ ._. CT_NNP scan_VB of_IN
        the_DT chest_NN ,_, abdomen_NN ,_, and_CC pelvis_NNS revealed_VBD bilateral_JJ pleural_NN
        effusions_NNS ,_, splenomegaly_RB ,_, and_CC axillary_JJ ,_, para-aortic_JJ ,_, and_CC
        inguinal_NN lymphadenopathy_NN ._. Stool_NNP 
        Clostridium_NNP difficile_NN toxin_NN B_NNP was_VBD
        negative_JJ ._. Because_IN of_IN her_PRP$ persistent_JJ diarrhea_NN ,_,
        hypoalbuminemia_NN ,_, and_CC anemia_NN ,_, an_DT upper_JJ endoscopy_NN and_CC
        flexible_JJ sigmoidoscopy_NN were_VBD performed_VBN on_IN hospital_NN day_NN #_# 8_CD
        to_TO exclude_VB a_DT protein_NN losing_VBG enteropathy_NN ._. Although_IN both_DT
        studies_NNS were_VBD endoscopically_RB normal_JJ ,_, histopathology_NN of_IN
        random_JJ mucosal_NN biopsies_NNS revealed_VBD characteristic_JJ features_NNS of_IN
        Crohn_NNP 's_POS disease_NN with_IN granulomas_NNS in_IN the_DT colon_NN and_CC erosive_JJ
        duodenitis_NNS with_IN a_DT single_JJ granuloma_NN in_IN the_DT small_JJ bowel_NN
        (_( Figure_NN 1_LS )_) ._. Anti-gliadin_NNP and_CC anti-endomysial_JJ antibodies_NNS
        were_VBD negative_JJ ._. On_IN hospital_NN day_NN #_# 9_CD ,_, a_DT bone_NN marrow_NN biopsy_NN
        revealed_VBD marked_VBN eosinophilia_NN and_CC multiple_JJ ,_, non-caseating_JJ
        granulomas_NNS ._. Flow_NNP cytometry_NN of_IN the_DT bone_NN marrow_NN and_CC
        peripheral_JJ blood_NN revealed_VBD no_DT evidence_NN of_IN malignancy_NN ._. AFB_NNP
        and_CC fungal_NN stains_NNS of_IN the_DT gastrointestinal_NN and_CC bone_NN marrow_NN
        biopsies_NNS were_VBD negative_JJ as_IN were_VBD cultures_NNS of_IN the_DT bone_NN marrow_NN
        6_CD weeks_NNS later_RB ._. A_DT PPD_NNP and_CC candida_NN control_NN were_VBD both_DT
        non-reactive_JJ ._.
        Given_VBN the_DT suspicion_NN of_IN a_DT systemic_JJ drug_NN reaction_NN as_IN the_DT
        etiology_NN of_IN her_PRP$ illness_NN ,_, the_DT patient_NN was_VBD given_VBN high_JJ dose_NN
        intravenous_JJ steroids_NNS for_IN three_CD days_NNS starting_VBG on_IN hospital_NN
        day_NN #_# 14_CD followed_VBN by_IN a_DT prednisone_NN taper_VB ._. Within_IN 24_CD hours_NNS ,_,
        the_DT patient_NN had_VBD a_DT rapid_JJ improvement_NN of_IN her_PRP$ diarrheal_NN
        symptoms_NNS followed_VBN by_IN resolution_NN of_IN her_PRP$ peripheral_JJ edema_NN and_CC
        lymphadenopathy_NN ._. There_EX were_VBD also_RB concomitant_NN improvements_NNS
        in_IN her_PRP$ hematological_JJ and_CC liver_NN profiles_NNS (_( Table_NNP 1_CD ,_, Figure_NN
        2_LS )_) ._. However_RB ,_, the_DT patient_NN developed_VBD generalized_JJ absence_NN
        seizures_NNS on_IN hospital_NN day_NN #_# 20_CD ._. Cerebrospinal_NNP fluid_JJ analysis_NN
        revealed_VBD an_DT isolated_VBN increased_VBN WBC_NNP of_IN 14_CD with_IN a_DT normal_JJ
        protein_NN level_NN ._. An_DT MRI_NNP of_IN the_DT brain_NN with_IN gadolinium_NN contrast_NN
        identified_VBD patchy_NN and_CC irregular_JJ signal_NN enhancement_NN in_IN the_DT
        gray_JJ matter_NN of_IN the_DT occipital_NN poles_NNS ,_, frontoparietal_NN regions_NNS ,_,
        and_CC cerebellar_NN hemispheres_NNS ._. The_DT patient_NN was_VBD started_VBN on_IN
        phenytoin_NN and_CC later_RB changed_VBN to_TO oxcarbazepine_NN ._. At_IN 1_CD month_NN
        post-discharge_JJ ,_, the_DT patient_NN was_VBD markedly_RB improved_VBN as_IN her_PRP$
        steroid_NN dose_NN was_VBD tapered_JJ ._. At_IN 3_CD months_NNS post-discharge_JJ ,_, a_DT
        repeat_NN upper_JJ and_CC lower_JJR endoscopy_NN with_IN terminal_NN ileum_NN
        intubation_NN and_CC random_JJ biopsies_NNS were_VBD normal_JJ ._. At_IN 7_CD months_NNS
        after_IN presentation_NN off_RP steroids_NNS ,_, the_DT patient_NN had_VBD completely_RB
        recovered_VBN with_IN no_DT evidence_NN of_IN residual_JJ hematological_JJ ,_,
        gastrointestinal_NN ,_, or_CC neurological_JJ sequelae_NN ._.
      
      
        Discussion_NNP
        Sulfasalazine_NNP is_VBZ a_DT widely_RB used_VBN anti-inflammatory_JJ agent_NN
        in_IN the_DT treatment_NN of_IN Crohn_NNP 's_POS disease_NN and_CC ulcerative_JJ colitis_NNS
        [_NN 1_CD 2_CD 3_CD ]_NN ._. Recent_JJ data_NNS has_VBZ demonstrated_VBN that_IN SSZ_NNP is_VBZ also_RB
        safe_JJ and_CC effective_JJ in_IN the_DT treatment_NN of_IN rheumatoid_NN arthritis_NN
        and_CC other_JJ rheumatological_JJ disorders_NNS [_NN 4_CD 5_CD ]_NN ._. Sulfasalazine_NNP
        is_VBZ a_DT dimer_NN composed_VBN of_IN 5_CD -_: aminosalicylic_JJ acid_NN linked_VBN by_IN an_DT
        azo_NN bond_NN to_TO sulfapyridine_NN ._. The_DT anti-inflammatory_JJ activity_NN
        of_IN SSZ_NNP is_VBZ due_JJ to_TO the_DT 5_CD -_: aminosalicylic_JJ acid_NN component_NN while_IN
        the_DT majority_NN of_IN the_DT adverse_JJ side_NN effects_NNS have_VBP been_VBN
        attributed_VBN to_TO the_DT sulfapyridine_NN moiety_NN [_NN 14_CD 15_CD 16_CD ]_NN ._.
        Fever_NN ,_, abdominal_NN pain_NN ,_, and_CC rash_NN may_MD develop_VB in_IN 3_CD %_NN to_TO 20_CD %_NN of_IN
        treated_VBN patients_NNS ,_, but_CC these_DT side_NN effects_NNS are_VBP usually_RB mild_JJ
        and_CC improve_VB with_IN dose_NN reduction_NN [_NN 7_CD 11_CD 12_CD ]_NN ._. Severe_NNP side_NN
        effects_NNS necessitating_VBG SSZ_NNP discontinuation_NN occur_VB in_IN less_JJR
        than_IN 5_CD %_NN of_IN treated_VBN patients_NNS [_NN 11_CD ]_NN ._.
        Our_PRP$ patient_NN developed_VBD a_DT severe_JJ systemic_JJ illness_NN
        following_VBG three_CD weeks_NNS of_IN SSZ_NNP therapy_NN for_IN rheumatoid_NN
        arthritis_NN ._. In_IN retrospect_NN ,_, her_PRP$ clinical_JJ presentation_NN with_IN
        rash_NN ,_, fever_NN ,_, and_CC lymphadenopathy_NN within_IN 4_CD weeks_NNS of_IN
        initiating_VBG treatment_NN is_VBZ consistent_JJ with_IN severe_JJ SSZ_NNP toxicity_NN
        [_NN 17_CD ]_NN ._. However_RB ,_, in_IN this_DT case_NN and_CC others_NNS ,_, it_PRP can_MD be_VB
        difficult_JJ to_TO distinguish_VB a_DT severe_JJ drug_NN reaction_NN from_IN other_JJ
        disease_NN processes_VBZ such_JJ as_IN infection_NN and_CC malignancy_NN ._. In_IN our_PRP$
        patient_NN 's_POS case_NN ,_, a_DT concern_NN of_IN lymphoma_NN was_VBD raised_VBN in_IN light_NN
        of_IN her_PRP$ underlying_VBG rheumatoid_NN arthritis_NN as_RB well_RB as_IN prominent_JJ
        lymphadenopathy_NN and_CC splenomegaly_RB ._. In_IN addition_NN ,_, a_DT possible_JJ
        opportunistic_JJ fungal_NN ,_, mycobacterial_NN ,_, or_CC other_JJ atypical_JJ
        infection_NN was_VBD raised_VBN with_IN the_DT high_JJ fevers_NNS ,_, low_JJ grade_NN DIC_NNP ,_,
        and_CC disseminated_VBN granulomas_NNS that_WDT persisted_VBD after_IN SSZ_NNP
        discontinuation_NN ._. Lastly_NNP ,_, Crohn_NNP 's_POS disease_NN or_CC ulcerative_JJ
        colitis_NNS with_IN extraintestinal_NN manifestations_NNS was_VBD a_DT
        possibility_NN with_IN her_PRP$ severe_JJ iron_NN deficiency_NN anemia_NN ,_,
        diarrhea_NN ,_, and_CC granulomatous_JJ enteritis_NNS ._. It_PRP was_VBD only_RB after_IN
        extensive_JJ evaluation_NN that_IN a_DT preliminary_JJ diagnosis_NN of_IN SSZ_NNP
        drug_NN toxicity_NN was_VBD made_VBN ._. Occult_NNP inflammatory_JJ bowel_NN disease_NN
        was_VBD not_RB definitively_RB excluded_VBN until_IN follow-up_JJ endoscopy_NN was_VBD
        repeated_VBN 3_CD months_NNS later_RB ._.
        This_DT patient_NN 's_POS clinical_JJ presentation_NN with_IN multi-organ_JJ
        involvement_NN due_JJ to_TO an_DT immunoallergic_JJ reaction_NN to_TO SSZ_NNP has_VBZ
        not_RB been_VBN previously_RB reported_VBN ._. The_DT gastrointestinal_NN mucosal_NN
        biopsies_NNS in_IN this_DT patient_NN demonstrated_VBD multiple_JJ
        non-caseating_JJ granulomas_NNS with_IN prominent_JJ eosinophilia_NN
        suggestive_JJ of_IN Crohn_NNP 's_POS disease_NN (_( Figure_NN 1_LS )_) ._. In_IN addition_NN ,_, the_DT
        patient_NN 's_POS bone_NN marrow_NN biopsy_NN also_RB demonstrated_VBD multiple_JJ
        non-caseating_JJ granulomas_NNS and_CC eosinophilia_NN ._. Although_IN other_JJ
        systemic_JJ illnesses_NNS such_JJ as_IN untreated_JJ tuberculosis_NNS ,_, Q_NNP fever_NN ,_,
        fungal_NN infections_NNS ,_, and_CC lymphoma_NN can_MD lead_VB to_TO
        gastrointestinal_NN granuloma_NN ,_, the_DT acute_JJ nature_NN of_IN this_DT
        patient_NN 's_POS symptoms_NNS and_CC rapid_JJ improvement_NN with_IN steroids_NNS make_VBP
        these_DT causes_NNS unlikely_JJ ._. Furthermore_RB ,_, special_JJ stains_NNS and_CC
        studies_NNS of_IN the_DT patient_NN 's_POS tissues_NNS revealed_VBD no_DT evidence_NN of_IN
        malignancy_NN or_CC infection_NN ._. To_TO our_PRP$ knowledge_NN ,_, only_RB one_CD other_JJ
        case_NN of_IN a_DT systemic_JJ granulomatous_JJ reaction_NN to_TO SSZ_NNP has_VBZ been_VBN
        reported_VBN which_WDT improved_VBD within_IN 24_CD hours_NNS of_IN SSZ_NNP
        discontinuation_NN [_NN 18_CD ]_NN ._. In_IN other_JJ cases_NNS of_IN granulomatous_JJ
        drug_NN reactions_NNS ,_, multi-organ_JJ involvement_NN with_IN fevers_NNS and_CC
        eosinophilia_NN have_VBP been_VBN reported_VBN [_NN 19_CD 20_CD ]_NN ._.
        Our_PRP$ patient_NN had_VBD severe_JJ cholestatic_JJ hepatitis_NN with_IN
        coagulopathy_NN ._. Although_IN Still_RB 's_POS disease_NN can_MD rarely_RB lead_VB to_TO
        hepatic_JJ involvement_NN with_IN cholestatic_JJ hepatitis_NN ,_, the_DT prior_JJ
        history_NN of_IN rheumatoid_NN factor_NN seropositivity_NN and_CC a_DT low_JJ serum_NN
        ferritin_NN level_NN made_VBD this_DT diagnosis_NN unlikely_JJ [_NN 21_CD ]_NN ._.
        Granulomatous_NNP hepatitis_NNP with_IN marked_VBD elevations_NNS in_IN serum_NN
        alkaline_NN phosphatase_NN and_CC granulomas_NNS on_IN liver_NN biopsy_NN have_VBP
        been_VBN reported_VBN in_IN patients_NNS with_IN SSZ_NNP hepatotoxicity_NN [_NN 22_CD 23_CD
        24_CD ]_NN ._. Although_IN liver_NN tissue_NN was_VBD not_RB obtained_VBN in_IN our_PRP$
        patient_NN ,_, the_DT predominance_NN of_IN serum_NN alkaline_NN phosphatase_NN and_CC
        bilirubin_NN level_NN elevations_NNS and_CC the_DT presence_NN of_IN granulomas_NNS
        in_IN other_JJ tissues_NNS suggest_VBP that_IN she_PRP probably_RB had_VBD
        granulomatous_JJ hepatitis_NN ._. The_DT presumed_VBN mechanism_NN of_IN liver_NN
        injury_NN in_IN SSZ_NNP hepatotoxicity_NN is_VBZ an_DT idiosyncratic_JJ
        hypersensitivity_NN response_NN ._. Both_DT severe_JJ hepatitis_NN and_CC acute_JJ
        liver_NN failure_NN have_VBP been_VBN attributed_VBN to_TO SSZ_NNP [_NN 25_CD 26_CD 27_CD 28_CD ]_NN ._.
        Patients_NNPS with_IN SSZ_NNP hepatotoxicity_NN demonstrate_VBP a_DT prompt_JJ
        recurrence_NN of_IN symptoms_NNS upon_IN rechallenge_NN with_IN SSZ_NNP or_CC
        sulfonamide_NN [_NN 15_CD 29_CD 30_CD 31_CD ]_NN ._. Susceptibility_NNP to_TO the_DT toxic_JJ
        effects_NNS of_IN SSZ_NNP and_CC other_JJ sulfonamides_NNS may_MD be_VB due_JJ to_TO the_DT
        interaction_NN of_IN metabolic_JJ pathways_NNS regulating_VBG N-_NNP acetylation_NN
        and_CC specific_JJ detoxification_NN of_IN the_DT metabolites_NNS of_IN the_DT drug_NN
        [_NN 32_CD 33_CD ]_NN ._. However_RB ,_, it_PRP remains_VBZ unclear_JJ if_IN genetic_JJ
        differences_NNS in_IN drug_NN metabolizing_VBG enzyme_NN expression_NN may_MD
        increase_VB the_DT risk_NN of_IN SSZ_NNP toxicity_NN ._.
        Myelotoxicity_NNP in_IN this_DT patient_NN was_VBD manifest_JJ by_IN leukopenia_NN
        and_CC neutropenia_NN (_( Table_NNP 1_LS )_) ._. SSZ_NNP has_VBZ previously_RB been_VBN
        associated_VBN with_IN neutropenia_NN with_IN an_DT estimated_VBN incidence_NN of_IN
        0_CD ._. 04_CD %_NN during_IN the_DT first_JJ 30_CD days_NNS of_IN treatment_NN [_NN 34_CD ]_NN ._. Bone_NNP
        marrow_NN biopsy_NN specimens_NNS of_IN patients_NNS with_IN SSZ_NNP induced_VBD
        agranulocytosis_NNS reveal_VBP a_DT paucity_NN of_IN myeloid_NN cells_NNS but_CC full_JJ
        recovery_NN typically_RB occurs_VBZ within_IN 10_CD days_NNS of_IN drug_NN
        discontinuation_NN [_NN 35_CD 36_CD 37_CD ]_NN ._. Although_IN our_PRP$ patient_NN had_VBD
        adequate_JJ myeloid_NN cells_NNS in_IN her_PRP$ bone_NN marrow_NN biopsy_NN ,_, she_PRP
        developed_VBD absolute_JJ neutropenia_NN by_IN hospital_NN day_NN #_# 19_CD that_WDT
        improved_VBD with_IN steroid_NN therapy_NN ._. SSZ_NNP induced_VBD agranulocytosis_NNS
        is_VBZ believed_VBN to_TO be_VB mediated_JJ by_IN immunological_JJ
        hypersensitivity_NN of_IN myeloid_NN precursors_NNS [_NN 38_CD ]_NN ._. Spontaneous_NNP
        recovery_NN from_IN SSZ_NNP agranulocytosis_NNS is_VBZ frequently_RB seen_VBN ,_,
        although_IN fatalities_NNS have_VBP been_VBN reported_VBN and_CC some_DT patients_NNS
        may_MD benefit_VB from_IN granulocyte_NN macrophage-colony_JJ stimulating_VBG
        factor_NN [_NN 39_CD 40_CD ]_NN ._.
        A_DT final_JJ clinical_JJ feature_NN of_IN SSZ_NNP toxicity_NN in_IN our_PRP$ patient_NN
        was_VBD the_DT development_NN of_IN seizures_NNS ._. Although_IN this_DT patient_NN had_VBD
        no_DT known_VBN risk_NN factors_NNS ,_, the_DT onset_NN of_IN seizures_NNS began_VBD in_IN
        combination_NN with_IN other_JJ clinical_JJ manifestations_NNS of_IN SSZ_NNP
        toxicity_NN ._. Interestingly_RB ,_, the_DT MRI_NNP demonstrated_VBD diffuse_NN gray_JJ
        matter_NN abnormalities_NNS ._. Although_IN central_JJ nervous_JJ system_NN
        vasculitis_NNS due_JJ to_TO immune_JJ complex_JJ deposition_NN or_CC drug-induced_JJ
        lupus_JJ is_VBZ a_DT possible_JJ etiology_NN of_IN seizures_NNS in_IN this_DT patient_NN ,_,
        there_EX was_VBD no_DT evidence_NN of_IN immune_JJ complex_JJ deposition_NN
        elsewhere_RB ._. Another_DT possibility_NN is_VBZ that_IN this_DT patient_NN may_MD
        have_VB developed_VBN CNS_NNP granulomas_NNS ._. Seizures_NNP have_VBP previously_RB
        been_VBN reported_VBN in_IN patients_NNS receiving_VBG SSZ_NNP ,_, often_RB in_IN the_DT
        setting_NN of_IN other_JJ clinical_JJ manifestations_NNS of_IN toxicity_NN [_NN 31_CD
        41_CD 42_CD ]_NN ._. Although_IN a_DT brain_NN biopsy_NN would_MD be_VB needed_VBN to_TO prove_VB
        our_PRP$ hypotheses_NNS ,_, there_EX is_VBZ a_DT precedent_NN for_IN other_JJ systemic_JJ
        granulomatous_JJ disorders_NNS such_JJ as_IN sarcoidosis_NNS leading_VBG to_TO CNS_NNP
        granuloma_NN formation_NN and_CC seizures_NNS [_NN 43_CD 44_CD ]_NN ._. Fortunately_RB ,_,
        this_DT patient_NN has_VBZ remained_VBN stable_JJ with_IN no_DT evidence_NN of_IN a_DT
        progressive_JJ neurological_JJ disorder_NN 7_CD months_NNS after_IN
        presentation_NN ._.
        Treatment_NNP of_IN severe_JJ adverse_JJ drug_NN reactions_NNS is_VBZ primarily_RB
        supportive_JJ once_RB a_DT diagnosis_NN has_VBZ been_VBN established_VBN and_CC the_DT
        offending_VBG agent_NN has_VBZ been_VBN discontinued_VBN ._. However_RB ,_, in_IN this_DT
        patient_NN 's_POS case_NN with_IN her_PRP$ prominent_JJ features_NNS of_IN a_DT
        hypersensitivity_NN reaction_NN and_CC failure_NN to_TO improve_VB after_IN SSZ_NNP
        discontinuation_NN ,_, corticosteroids_NNS were_VBD administered_VBN to_TO
        hasten_VB recovery_NN ._. Fortunately_RB ,_, most_JJS of_IN her_PRP$ clinical_JJ symptoms_NNS
        promptly_RB improved_VBN after_IN steroids_NNS were_VBD begun_VBN ._. The_DT use_NN of_IN
        steroids_NNS in_IN the_DT setting_NN of_IN SSZ_NNP toxicity_NN is_VBZ controversial_JJ
        and_CC not_RB always_RB effective_JJ ._. In_IN cases_NNS of_IN fulminant_NN hepatic_JJ
        failure_NN and_CC agranulocytosis_NNS ,_, several_JJ patients_NNS have_VBP died_VBN
        despite_IN the_DT use_NN of_IN steroids_NNS [_NN 27_CD 28_CD 37_CD ]_NN ._. Intravenous_NNP
        immunoglobulin_NN was_VBD reported_VBN as_IN a_DT successful_JJ "_'' rescue_NN "_''
        therapy_NN in_IN a_DT patient_NN with_IN SSZ_NNP induced_VBD fulminant_NN hepatic_JJ
        failure_NN and_CC erythroid_NN hypoplasia_NN who_WP had_VBD not_RB responded_VBN to_TO
        steroids_NNS [_NN 25_CD ]_NN ._. Due_JJ to_TO the_DT infrequent_JJ occurrence_NN of_IN
        severe_JJ SSZ_NNP toxicity_NN that_WDT does_VBZ not_RB improve_VB with_IN drug_NN
        discontinuation_NN ,_, it_PRP is_VBZ unlikely_JJ that_IN randomized_JJ controlled_VBN
        trials_NNS of_IN steroids_NNS or_CC other_JJ interventions_NNS will_MD be_VB
        performed_VBN ._. It_PRP appears_VBZ reasonable_JJ to_TO reserve_VB steroids_NNS for_IN
        patients_NNS with_IN severe_JJ systemic_JJ SSZ_NNP toxicity_NN that_WDT fail_VBP to_TO
        respond_VB to_TO supportive_JJ care_NN following_VBG drug_NN
        discontinuation_NN ._.
      
      
        Conclusions_NNP
        Sulfasalazine_NNP is_VBZ a_DT commonly_RB used_VBN and_CC effective_JJ
        medication_NN in_IN the_DT treatment_NN of_IN inflammatory_JJ bowel_NN disease_NN
        and_CC various_JJ rheumatologic_JJ disorders_NNS ._. Side_NN effects_NNS usually_RB
        develop_VBP within_IN 3_CD months_NNS of_IN treatment_NN and_CC are_VBP frequently_RB
        managed_VBN with_IN dose_NN adjustments_NNS ._. However_RB ,_, there_EX is_VBZ a_DT subset_NN
        of_IN patients_NNS who_WP may_MD develop_VB severe_JJ and_CC unusual_JJ systemic_JJ
        side_NN effects_NNS ._. Although_IN rheumatology_NN patients_NNS may_MD be_VB at_IN
        increased_VBN risk_NN of_IN SSZ_NNP toxicity_NN compared_VBN to_TO IBD_NNP patients_NNS ,_,
        there_EX are_VBP no_DT reliable_JJ laboratory_NN or_CC clinical_JJ predictors_NNS of_IN
        SSZ_NNP toxicity_NN [_NN 45_CD ]_NN ._. Therefore_RB ,_, practicing_VBG physicians_NNS
        should_MD be_VB aware_JJ of_IN the_DT potential_NN for_IN severe_JJ ,_, unexplained_JJ
        granulomatous_JJ reactions_NNS to_TO SSZ_NNP that_WDT can_MD mimic_VB other_JJ
        infectious_JJ ,_, malignant_JJ ,_, and_CC autoimmune_JJ conditions_NNS ._. Fever_NN ,_,
        rash_NN ,_, and_CC eosinophilia_NN developing_VBG within_IN 3_CD months_NNS of_IN
        initiating_VBG SSZ_NNP should_MD alert_VB the_DT clinician_NN to_TO the_DT
        possibility_NN of_IN a_DT drug_NN reaction_NN ._. Patients_NNS with_IN SSZ_NNP toxicity_NN
        should_MD avoid_VB exposure_NN to_TO all_DT sulfonamide_NN containing_VBG drugs_NNS
        due_JJ to_TO potential_JJ cross-reactivity_JJ ._. In_IN addition_NN ,_, some_DT
        inflammatory_JJ bowel_NN disease_NN patients_NNS have_VBP demonstrated_VBN
        cross-reactivity_JJ to_TO 5_CD -_: ASA_NNP products_NNS [_NN 11_CD ]_NN ._. If_IN severe_JJ
        symptoms_NNS do_VBP not_RB resolve_VB with_IN SSZ_NNP discontinuation_NN ,_, a_DT short_JJ
        course_NN of_IN corticosteroids_NNS may_MD be_VB of_IN benefit_NN ._.
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD
      
    
  
